Monday, May 20, 2013

RuiYi Inc. and Genor Biopharma have entered into a collaboration for the development of novel anti IL-6 monoclonal antibody - RYI-008 in China

RuiYi Inc. and Genor Biopharma have entered into a collaboration for the development of novel anti IL-6 monoclonal antibody - RYI-008 in China. As per the agreement Genor will be responsible for the development of RYI-008 in China. RYI-008 has an unprecedented femtomolar potency and amazing long half-life, hence has a therapeutic profile of once monthly, low milligram, subcutaneous dosing.

RYI-008, also known as ARGX-109, is a novel, extremely potent monoclonal antibody that is highly selective to IL-6, a cytokine widely implicated in inflammation and cancer. The antibody was discovered by arGEN-X, Ghent Belgium, utilizing the arGEN-X SIMPLE Antibody™ technology, and exclusively license to RuiYi to develop and commercialize globally